<DOC>
	<DOCNO>NCT02458729</DOCNO>
	<brief_summary>The aim study conduct prospective , randomize , double-blind study ass efficacy safety thromboprophylaxis rivaroxaban total knee arthroplasty patient tranexamic acid use bleed prophylaxis .</brief_summary>
	<brief_title>The Blood Saving Effect Tranexamic Acid Total Knee Arthroplasty With Rivaroxaban Thromboprophylaxis</brief_title>
	<detailed_description>Total knee arthroplasty effective procedure end-stage arthritis knee term pain relief functional recovery . However , procedure associate substantial perioperative blood loss . As high 69 % allogeneic blood transfusion rate report patient receive total knee arthroplasty preoperative haemoglabin level &lt; 13 g/dl . Tranexamic acid ( TXA ) , antifibrinolytic , give intraoperatively , report effective reduce one third postoperative blood loss standard total knee arthroplasty . Our previous study show TXA reduce total blood loss 1453mL 833mL ( p &lt; 0.001 ) need transfusion 20 % 4 % ( p=0.014 ) total knee patient enoxaparin ( Clexane ; Glaxo-Smith-Kline , Brentford , United Kindom ) thromboprophylaxis . In recent year , effective practical method thrombophylaxis total hip knee replacement surgery . Rivaroxaban one first oral factor Xa inhibitor license regard . The advantage rivaroxaban include oral administration , need monitor blood level dose adjustment convenient short hospital stay contemporary total knee arthroplasty . Its efficacy prevent venous thromboembolism ( VTE ) total knee arthroplasty extensitvely investigate RECORD ( Regulation Coagulation Orthopaedic surgery prevent Deep-vein thrombosis pulmonary embolism ) 3 4 study , result show rivaroxaban 10mg daily superior enoxaparin 40mg subcutaneously daily 30mg every 12 hour 10 14 day . Despite clinical efficacy VTE prophylaxis , orthopaedic surgeon still sceptic routine use rivaroxaban knee hip surgery concern increase risk bleed complication . A high reoperation rate regard wound complication within 30 day hip knee replacement rivaroxaban group tinzaparin group ( 2.94 % versus 1.8 % ) report recently . Similar event report study . However , study use TXA bleed prophylaxis hip knee replacement surgery . The risk increase VTE use TXA , owe antifibrinolytic effect , cause concern . The aim study conduct prospective , randomize , double-blind study ass efficacy safety thromboprophylaxis rivaroxaban total knee arthroplasty patient TXA use bleed prophylaxis .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Tranylcypromine</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Endstage arthritis knee Failure medical treatment rehabilitation Hemoglobin &gt; 10g/dl No use nonsteroid antiinflammatory agent one week operation Preoperative Hemoglobin â‰¦10 g/dl History infection intraarticular fracture affective knee Renal function deficiency ( GFR &lt; 55 ml/min/1.73m2 ) relative contraindicate venography Elevated liver enzyme , history liver cirrhosis , impair liver function coagulopathy ( include longterm use anticoagulant ) History deep vein thrombosis , ischemic heart disease stroke</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Tranexamic Acid</keyword>
	<keyword>Total Knee Arthroplasty</keyword>
	<keyword>Rivaroxaban</keyword>
</DOC>